LifeMD Accused of Prioritizing Prescription Speed Over Patient Safety in GLP-1 Telehealth

Former employees of LifeMD, a telehealth company promoted in connection with Novo Nordisk's obesity drug programs, allege that clinicians were pressured to prescribe faster with less screening and inadequate follow-up. The accusations raise serious questions about whether the platform's clinical workflows were designed around patient safety or revenue throughput.

Why it matters

LifeMD built its profile in part through visibility tied to the GLP-1 obesity treatment wave. Former employees now allege the company pushed clinicians to move patients through prescribing workflows faster, with less time spent on screening and less infrastructure for ongoing monitoring. These are not minor procedural complaints. Adequate screening and follow-up are the clinical substance of safe prescribing, not administrative overhead.

The broader issue here is structural. Telehealth platforms that generate revenue per prescription have a built-in incentive misalignment with the deliberate, longitudinal work that responsible prescribing requires. Clinicians working inside these systems need to understand that employment contracts and productivity metrics do not override their professional and legal obligations. And health systems evaluating telehealth partnerships need to ask hard questions about how clinical decisions are actually made inside these platforms before they lend their brand or their patients to them.

What to watch

Whether state medical boards or the FTC move to establish enforceable clinical standards for telehealth prescribing platforms, particularly for controlled and high-demand medications.